Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New radioactive drug targets tough melanoma

NCT ID NCT07076550

First seen Jan 04, 2026 · Last updated May 25, 2026 · Updated 23 times

Summary

This early-stage trial tests an investigational drug for adults with melanoma that has spread or cannot be surgically removed. The main goals are to find the safest dose and understand side effects. Participants receive the drug once every 6 weeks for up to 6 doses, with regular checkups. The study is currently recruiting 50 people.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA, METASTATIC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Alfred Health

    RECRUITING

    Melbourne, Victoria, 3004, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Austin Health

    RECRUITING

    Melbourne, Victoria, 3084, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Fiona Stanley Hospital

    NOT_YET_RECRUITING

    Murdoch, Western Australia, 6150, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • GenesisCare Murdoch

    NOT_YET_RECRUITING

    Murdoch, Western Australia, 6150, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.